Informations générales (source: ClinicalTrials.gov)
ACCEPTABILITY AND WRITING FREQUENCY OF ADVANCED DIRECTIVES IN ONCO-DERMATOLOGY PATIENTS (PADAONCODERM)
Observational
Central Hospital, Nancy, France (Voir sur ClinicalTrials)
janvier 2019
juin 2019
29 juin 2024
The law about advance directives is evolving but, in France, few people write it.
Te main endpoint of this research is to estimate the proportion of patients who have
written their advance directives or considering doing so in onco-dermatologic population.
If this rate remains low, some insights on the reasons will be able to be advanced
looking at the point of view and opinion of patients about this topic.
Seconds endpoints are :
For patients against or not planning to write it, understand their reasons
Estimate the proportion of patients requesting information and understand how they would
like to receive it.
Investigate a possible association between the stage of the oncological disease and the
positioning of the patient concerning advance directives.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHRU Nancy-Brabois hospital - 54500 - Vandœuvre-lès-Nancy - France | anne-claire Bursztejn | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
> 18 ya
With one of the diagnoses below:
- Melanoma
- Skin lymphoma
- Meckel Carcinoma
- localy advanced or metastatic Basal cell carcinoma or squamous cell carcinoma
> 18 ya
With one of the diagnoses below:
- Melanoma
- Skin lymphoma
- Meckel Carcinoma
- localy advanced or metastatic Basal cell carcinoma or squamous cell carcinoma
Patients not in possession of all of its cognitive abilities Patients who can't read
patients who don't speak french